Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.

LeBlanc FR, Pearson JM, Tan SF, Cheon H, Xing JC, Dunton W, Feith DJ, Loughran TP Jr.

Br J Haematol. 2020 Mar 2. doi: 10.1111/bjh.16530. [Epub ahead of print]

PMID:
32124438
2.

Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia.

Cheon H, Dziewulska KH, Moosic KB, Olson KC, Gru AA, Feith DJ, Loughran TP Jr.

Curr Hematol Malig Rep. 2020 Feb 15. doi: 10.1007/s11899-020-00565-6. [Epub ahead of print] Review.

PMID:
32062772
3.

Whole Genome Sequencing of Spontaneously Occurring Rat Natural Killer Large Granular Lymphocyte Leukemia Identifies JAK1 Somatic Activating Mutation.

Wang TT, Yang J, Dighe S, Schmachtenberg MW, Leigh NT, Farber E, Onengut-Gumuscu S, Feith DJ, Ratan A, Loughran TP Jr, Olson TL.

Cancers (Basel). 2020 Jan 3;12(1). pii: E126. doi: 10.3390/cancers12010126.

4.

Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia.

Pearson JM, Tan SF, Sharma A, Annageldiyev C, Fox TE, Abad JL, Fabrias G, Desai D, Amin S, Wang HG, Cabot MC, Claxton DF, Kester M, Feith DJ, Loughran TP.

Mol Cancer Res. 2020 Mar;18(3):352-363. doi: 10.1158/1541-7786.MCR-19-0619. Epub 2019 Nov 19.

PMID:
31744877
5.

Retroviral sero-reactivity in LGL leukaemia patients and family members.

Nyland SB, Feith DJ, Poss M, Olson TL, Krissinger DJ, Poiesz BJ, Ruscetti FW, Loughran TP Jr.

Br J Haematol. 2020 Feb;188(4):522-527. doi: 10.1111/bjh.16223. Epub 2019 Oct 14.

PMID:
31608437
6.

Genomics of LGL leukemia and select other rare leukemia/lymphomas.

Moosic KB, Paila U, Olson KC, Dziewulska K, Wang TT, Xing JC, Ratan A, Feith DJ, Loughran TP Jr, Olson TL.

Best Pract Res Clin Haematol. 2019 Sep;32(3):196-206. doi: 10.1016/j.beha.2019.06.003. Epub 2019 Jun 6. Review.

PMID:
31585620
7.

Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.

Barth BM, Wang W, Toran PT, Fox TE, Annageldiyev C, Ondrasik RM, Keasey NR, Brown TJ, Devine VG, Sullivan EC, Cote AL, Papakotsi V, Tan SF, Shanmugavelandy SS, Deering TG, Needle DB, Stern ST, Zhu J, Liao J, Viny AD, Feith DJ, Levine RL, Wang HG, Loughran TP Jr, Sharma A, Kester M, Claxton DF.

Blood Adv. 2019 Sep 10;3(17):2598-2603. doi: 10.1182/bloodadvances.2018021295. No abstract available.

8.

Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells.

Kao LP, Morad SAF, Davis TS, MacDougall MR, Kassai M, Abdelmageed N, Fox TE, Kester M, Loughran TP Jr, Abad JL, Fabrias G, Tan SF, Feith DJ, Claxton DF, Spiegel S, Fisher-Wellman KH, Cabot MC.

J Lipid Res. 2019 Sep;60(9):1590-1602. doi: 10.1194/jlr.RA119000251. Epub 2019 Jul 30.

PMID:
31363040
9.

Retrovirus insertion site analysis of LGL leukemia patient genomes.

Li W, Yang L, Harris RS, Lin L, Olson TL, Hamele CE, Feith DJ, Loughran TP Jr, Poss M.

BMC Med Genomics. 2019 Jun 17;12(1):88. doi: 10.1186/s12920-019-0549-9.

10.

The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia.

Annageldiyev C, Gowda K, Patel T, Bhattacharya P, Tan SF, Iyer S, Desai D, Dovat S, Feith DJ, Loughran TP Jr, Amin S, Claxton D, Sharma A.

Haematologica. 2020 Mar;105(3):687-696. doi: 10.3324/haematol.2018.212886. Epub 2019 May 23.

11.

Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen.

Morad SAF, MacDougall MR, Abdelmageed N, Kao LP, Feith DJ, Tan SF, Kester M, Loughran TP Jr, Wang HG, Cabot MC.

Exp Cell Res. 2019 Aug 15;381(2):256-264. doi: 10.1016/j.yexcr.2019.05.021. Epub 2019 May 18.

12.

Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Tan SF, Dunton W, Liu X, Fox TE, Morad SAF, Desai D, Doi K, Conaway MR, Amin S, Claxton DF, Wang HG, Kester M, Cabot MC, Feith DJ, Loughran TP Jr.

J Lipid Res. 2019 Jun;60(6):1078-1086. doi: 10.1194/jlr.M091876. Epub 2019 Apr 8.

PMID:
30962310
13.

Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes.

Olson KC, Kulling Larkin PM, Signorelli R, Hamele CE, Olson TL, Conaway MR, Feith DJ, Loughran TP Jr.

Cytokine. 2018 Nov;111:551-562. doi: 10.1016/j.cyto.2018.09.016. Epub 2018 Nov 17.

14.

IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability.

Wang TT, Yang J, Zhang Y, Zhang M, Dubois S, Conlon KC, Tagaya Y, Hamele CE, Dighe S, Olson TL, Feith DJ, Azimi N, Waldmann TA, Loughran TP Jr.

Leukemia. 2019 May;33(5):1243-1255. doi: 10.1038/s41375-018-0290-y. Epub 2018 Oct 23.

15.

TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia.

Yang J, LeBlanc FR, Dighe SA, Hamele CE, Olson TL, Feith DJ, Loughran TP Jr.

Blood. 2018 Jun 21;131(25):2803-2815. doi: 10.1182/blood-2017-09-808816. Epub 2018 Apr 26.

16.

Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia.

Kulling PM, Olson KC, Hamele CE, Toro MF, Tan SF, Feith DJ, Loughran TP Jr.

PLoS One. 2018 Feb 23;13(2):e0193429. doi: 10.1371/journal.pone.0193429. eCollection 2018.

17.

Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.

Kulling PM, Olson KC, Olson TL, Hamele CE, Carter KN, Feith DJ, Loughran TP Jr.

J Steroid Biochem Mol Biol. 2018 Mar;177:140-148. doi: 10.1016/j.jsbmb.2017.07.009. Epub 2017 Jul 20.

18.

The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.

Tan SF, Pearson JM, Feith DJ, Loughran TP Jr.

Expert Opin Ther Targets. 2017 Jun;21(6):583-590. doi: 10.1080/14728222.2017.1322065. Epub 2017 May 2. Review.

19.

Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.

Morad SAF, Davis TS, MacDougall MR, Tan SF, Feith DJ, Desai DH, Amin SG, Kester M, Loughran TP Jr, Cabot MC.

Biochem Pharmacol. 2017 Apr 15;130:21-33. doi: 10.1016/j.bcp.2017.02.002. Epub 2017 Feb 9.

20.

Acid ceramidase is upregulated in AML and represents a novel therapeutic target.

Tan SF, Liu X, Fox TE, Barth BM, Sharma A, Turner SD, Awwad A, Dewey A, Doi K, Spitzer B, Shah MV, Morad SA, Desai D, Amin S, Zhu J, Liao J, Yun J, Kester M, Claxton DF, Wang HG, Cabot MC, Schuchman EH, Levine RL, Feith DJ, Loughran TP Jr.

Oncotarget. 2016 Dec 13;7(50):83208-83222. doi: 10.18632/oncotarget.13079.

21.

Vitamin D in hematological disorders and malignancies.

Kulling PM, Olson KC, Olson TL, Feith DJ, Loughran TP Jr.

Eur J Haematol. 2017 Mar;98(3):187-197. doi: 10.1111/ejh.12818. Epub 2016 Nov 21. Review.

22.

Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia.

Olson KC, Kulling PM, Olson TL, Tan SF, Rainbow RJ, Feith DJ, Loughran TP Jr.

Cancer Biol Ther. 2017 May 4;18(5):290-303. doi: 10.1080/15384047.2016.1235669. Epub 2016 Oct 7.

23.

Carcinogen-specific mutations in preferred Ras-Raf pathway oncogenes directed by strand bias.

Keller RR, Gestl SA, Lu AQ, Hoke A, Feith DJ, Gunther EJ.

Carcinogenesis. 2016 Aug;37(8):810-816. doi: 10.1093/carcin/bgw061. Epub 2016 May 17.

24.

Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.

Morad SA, Ryan TE, Neufer PD, Zeczycki TN, Davis TS, MacDougall MR, Fox TE, Tan SF, Feith DJ, Loughran TP Jr, Kester M, Claxton DF, Barth BM, Deering TG, Cabot MC.

J Lipid Res. 2016 Jul;57(7):1231-42. doi: 10.1194/jlr.M067389. Epub 2016 May 2.

25.

Combinatorial interventions inhibit TGFβ-driven epithelial-to-mesenchymal transition and support hybrid cellular phenotypes.

Steinway SN, Zañudo JGT, Michel PJ, Feith DJ, Loughran TP, Albert R.

NPJ Syst Biol Appl. 2015 Nov 26;1:15014. doi: 10.1038/npjsba.2015.14. eCollection 2015.

26.

Skin Carcinogenesis Studies Using Mouse Models with Altered Polyamines.

Nowotarski SL, Feith DJ, Shantz LM.

Cancer Growth Metastasis. 2015 Aug 9;8(Suppl 1):17-27. doi: 10.4137/CGM.S21219. eCollection 2015. Review.

27.

Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.

LeBlanc FR, Liu X, Hengst J, Fox T, Calvert V, Petricoin EF 3rd, Yun J, Feith DJ, Loughran TP Jr.

Cancer Biol Ther. 2015;16(12):1830-40. doi: 10.1080/15384047.2015.1078949.

28.

Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.

Morad SA, Tan SF, Feith DJ, Kester M, Claxton DF, Loughran TP Jr, Barth BM, Fox TE, Cabot MC.

Biochim Biophys Acta. 2015 Jul;1851(7):919-28. doi: 10.1016/j.bbalip.2015.03.001. Epub 2015 Mar 10.

29.

Emergence of a STAT3 mutated NK clone in LGL leukemia.

Yan Y, Olson TL, Nyland SB, Feith DJ, Loughran TP Jr.

Leuk Res Rep. 2014 Dec 16;4(1):4-7. doi: 10.1016/j.lrr.2014.12.001. eCollection 2015.

30.

Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.

Hasanali ZS, Epner EM, Feith DJ, Loughran TP Jr, Sample CE.

Mol Cancer Ther. 2014 Dec;13(12):2784-92. doi: 10.1158/1535-7163.MCT-14-0593. Epub 2014 Oct 15.

31.

Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.

Sun X, Hasanali ZS, Chen A, Zhang D, Liu X, Wang HG, Feith DJ, Loughran TP Jr, Xu K.

Br J Haematol. 2015 Feb;168(3):371-83. doi: 10.1111/bjh.13143. Epub 2014 Oct 4.

32.

Network modeling of TGFβ signaling in hepatocellular carcinoma epithelial-to-mesenchymal transition reveals joint sonic hedgehog and Wnt pathway activation.

Steinway SN, Zañudo JG, Ding W, Rountree CB, Feith DJ, Loughran TP Jr, Albert R.

Cancer Res. 2014 Nov 1;74(21):5963-77. doi: 10.1158/0008-5472.CAN-14-0225. Epub 2014 Sep 4.

33.

C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia.

Ryland LK, Doshi UA, Shanmugavelandy SS, Fox TE, Aliaga C, Broeg K, Baab KT, Young M, Khan O, Haakenson JK, Jarbadan NR, Liao J, Wang HG, Feith DJ, Loughran TP Jr, Liu X, Kester M.

PLoS One. 2013 Dec 19;8(12):e84648. doi: 10.1371/journal.pone.0084648. eCollection 2013.

34.

Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation.

Lange I, Geerts D, Feith DJ, Mocz G, Koster J, Bachmann AS.

J Mol Biol. 2014 Jan 23;426(2):332-46. doi: 10.1016/j.jmb.2013.09.037. Epub 2013 Oct 1.

35.

Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.

Morad SA, Levin JC, Tan SF, Fox TE, Feith DJ, Cabot MC.

Biochim Biophys Acta. 2013 Dec;1831(12):1657-64. doi: 10.1016/j.bbalip.2013.07.016. Epub 2013 Aug 9.

PMID:
23939396
36.

DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.

Koomoa DL, Geerts D, Lange I, Koster J, Pegg AE, Feith DJ, Bachmann AS.

Int J Oncol. 2013 Apr;42(4):1219-28. doi: 10.3892/ijo.2013.1835. Epub 2013 Feb 21.

37.

Targeted expression of ornithine decarboxylase antizyme prevents upper aerodigestive tract carcinogenesis in p53-deficient mice.

Feith DJ, Pegg AE, Fong LY.

Carcinogenesis. 2013 Mar;34(3):570-6. doi: 10.1093/carcin/bgs377. Epub 2012 Dec 7.

38.

S-adenosylmethionine decarboxylase overexpression inhibits mouse skin tumor promotion.

Shi C, Cooper TK, McCloskey DE, Glick AB, Shantz LM, Feith DJ.

Carcinogenesis. 2012 Jul;33(7):1310-8. doi: 10.1093/carcin/bgs184. Epub 2012 May 19.

39.

Characterization of transgenic mice with overexpression of spermidine synthase.

Shi C, Welsh PA, Sass-Kuhn S, Wang X, McCloskey DE, Pegg AE, Feith DJ.

Amino Acids. 2012 Feb;42(2-3):495-505. doi: 10.1007/s00726-011-1028-6. Epub 2011 Aug 2.

40.

Carcinogenesis studies in mice with genetically engineered alterations in polyamine metabolism.

Feith DJ.

Methods Mol Biol. 2011;720:129-41. doi: 10.1007/978-1-61779-034-8_7.

PMID:
21318870
41.

The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.

Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS.

Int J Cancer. 2010 May 1;126(9):2012-24. doi: 10.1002/ijc.25074.

42.

Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma.

Koomoa DL, Borsics T, Feith DJ, Coleman CC, Wallick CJ, Gamper I, Pegg AE, Bachmann AS.

Mol Cancer Ther. 2009 Jul;8(7):2067-75. doi: 10.1158/1535-7163.MCT-08-1217. Epub 2009 Jul 7.

43.

Studies of the mechanism by which increased spermidine/spermine N1-acetyltransferase activity increases susceptibility to skin carcinogenesis.

Wang X, Feith DJ, Welsh P, Coleman CS, Lopez C, Woster PM, O'Brien TG, Pegg AE.

Carcinogenesis. 2007 Nov;28(11):2404-11. Epub 2007 Aug 3.

PMID:
17675337
44.

Polyamines and neoplastic growth.

Pegg AE, Feith DJ.

Biochem Soc Trans. 2007 Apr;35(Pt 2):295-9.

PMID:
17371264
45.

Mouse skin chemical carcinogenesis is inhibited by antizyme in promotion-sensitive and promotion-resistant genetic backgrounds.

Feith DJ, Shantz LM, Shoop PL, Keefer KA, Prakashagowda C, Pegg AE.

Mol Carcinog. 2007 Jun;46(6):453-65.

PMID:
17219416
46.

Tumor suppressor activity of ODC antizyme in MEK-driven skin tumorigenesis.

Feith DJ, Origanti S, Shoop PL, Sass-Kuhn S, Shantz LM.

Carcinogenesis. 2006 May;27(5):1090-8. Epub 2006 Jan 7.

PMID:
16400186
47.

Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.

Wallick CJ, Gamper I, Thorne M, Feith DJ, Takasaki KY, Wilson SM, Seki JA, Pegg AE, Byus CV, Bachmann AS.

Oncogene. 2005 Aug 25;24(36):5606-18.

PMID:
16007177
48.

Induction of ornithine decarboxylase activity is a necessary step for mitogen-activated protein kinase kinase-induced skin tumorigenesis.

Feith DJ, Bol DK, Carboni JM, Lynch MJ, Sass-Kuhn S, Shoop PL, Shantz LM.

Cancer Res. 2005 Jan 15;65(2):572-8.

49.

Ornithine decarboxylase is a target for chemoprevention of basal and squamous cell carcinomas in Ptch1+/- mice.

Tang X, Kim AL, Feith DJ, Pegg AE, Russo J, Zhang H, Aszterbaum M, Kopelovich L, Epstein EH Jr, Bickers DR, Athar M.

J Clin Invest. 2004 Mar;113(6):867-75.

Supplemental Content

Loading ...
Support Center